Richard E. Chaisson, MD

CRS:

JHU

Role:

Investigators

Position:

Co-investigator

Richard E. Chaisson, M.D., is Professor of Medicine, Epidemiology and International Health at the Johns Hopkins University in Baltimore.  He received his BS and MD degrees from the University of Massachusetts, and was an intern, resident and fellow at the University of California, San Francisco, where he was also Assistant Professor of Medicine.  From 1988-1998 he was director of the Johns Hopkins AIDS Service, and he co-founded the Johns Hopkins HIV Clinic cohort, an observational study that has been the source of more than 130 scientific publications on the outcomes of HIV disease and its treatment. 

Dr. Chaisson is currently Director of the Johns Hopkins Center for Tuberculosis Research, a multidisciplinary center with more than $60 million in grants for the study of TB from bench to bedside. Dr. Chaisson's research interests focus on tuberculosis and HIV infection, including global epidemiology, clinical trials, diagnostics and public health interventions.  He is currently principal investigator of 11 research grants, and is director of the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), an international research consortium funded by the Bill and Melinda Gates Foundation to assess the impact of novel strategies for controlling HIV-related TB.  He has published over 300 scientific papers and book chapters.

  • Chair, ACTG Tuberculosis TSG
  • Member, Scientific Agenda Steering Committee (SASC)
  • Chair ACTG 5279
  • Co-chair ACTG 5344
  • Member, TB Infection Control Standards Working Group of the AEC, June 2016
  • Protocol Team Member ACTG 5300, ACTG 5312, ACTG 5349

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More